Parabilis Medicines, Inc. Common Stock
PBLSStock
$26.59
Market Cap—
P/E—
Div yield—
Beta—
Price Chart
Industry Peers — Pharmaceuticals(555)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PBLSParabilis Medicines, Inc. Common Stock | — | — | — | $26.59 |
| LLYEli Lilly & Co. | D | B | B | $1122.50 |
| JNJJohnson & Johnson | D | C | C | $235.18 |
| ABBVABBVIE INC. | D | C | C | $222.47 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $150.93 |
| AZNAstraZeneca PLC | C | B | C | $178.71 |
| NVONovo-Nordisk A/S | B | B | C | $43.55 |
| ABTAbbott Laboratories | C | C | D | $90.62 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | B | $32.91 |
About
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.